Roche has reported its first-quarter revenues for 2026, revealing a 5% decline in reported sales to CHF 14.77 billion. However, the company emphasized that this drop was primarily driven by the appreciation of the Swiss franc. At constant exchange rates, the group actually saw a 6% increase in revenue, signaling that the underlying business remains robust and on track to meet its annual mid-single-digit growth targets.
The pharmaceutical division contributed CHF 11.47 billion, bolstered by the performance of key blockbuster treatments. Ocrevus for multiple sclerosis, Hemlibra for haemophilia A, and the ophthalmology drug Vabysmo all maintained strong market momentum. Additionally, the mature product Xolair experienced a 26% surge in sales following its recent indication expansion into food allergy treatment.
CEO Thomas Schinecker described the quarter as a “strong start,” highlighting significant progress in the clinical pipeline. Recent positive readouts in obesity, severe autoimmune diseases, and multiple sclerosis provide a foundation for future regulatory filings. Despite the currency headwinds—exacerbated by Roche’s $50 billion investment strategy in the U.S. to mitigate potential tariffs—the company remains optimistic. Schinecker projects that Roche could launch up to 19 new medicines by 2030, leveraging its diversified portfolio to navigate the current volatile geopolitical landscape.
Source: https://pharmaphorum.com/news/swiss-franc-strength-puts-roches-results-poor-light